Further studies are warranted to confirm the role of RAD51B in conferring breast and ovarian cancer susceptibility in additional populations and to define the inclusion of RAD51B in panels for genetic risk prediction multigene assays. This evidence concerns the gene RAD51B and ovarian carcinoma.